Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an announcement.
Clarity Pharmaceuticals Ltd has announced the quotation of 95,622 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code CU6, effective from November 10, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its shareholders, potentially strengthening its position in the radiopharmaceutical sector.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd operates in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is known for its innovative approach in targeting specific cancer types using its proprietary technology.
Average Trading Volume: 2,959,118
Technical Sentiment Signal: Buy
Current Market Cap: A$1.69B
See more data about CU6 stock on TipRanks’ Stock Analysis page.